Ibrahim Aldoss, MD

Conference Coverage

Augment-101 Study Shows Revumenib Yields High Overall Response Rate for Patients With Heavily Pretreated KMT2Ar Acute Leukemia

12/13/2023

Ibrahim Aldoss , MD;

At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.

At the 65th ASH Annual Meeting,...

12/13/2023

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Ibrahim Aldoss, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products